Aliment Pharmacol Ther 1995; 9: 713–721.

Index

5-aminosalicyclic acid, 557
5-ASA, 315
acetamiophen, 1
achalasia, 599
acid secretion, 107, 331
acid suppression, 191
acid, 167
acute duodenal ulcers, 411
acute viral hepatitis, 699
adaptation, 379, 655
Adler, M. *see* Thomson, A.B.R.
adrenegic agonists, 179
Aggestrup, S. *see* Hendel, J.
AIDS, 553
Al-Assi, M.T. *see* Yousfi, M.M.
Albanese, A., Bentivoglio, A.R., Cassetta, E., Viggiano, A., Maria, G. & Gui, D., Review article: the use of botulinum toxin in the alimentary tract, 599
alcohol dehydrogenase, 57
alpha-interferon, 535
aminopyrine breath test, 263
aminosalicyclic acid, 491
aminosalicylate, 293
amoxycillin, 41, 205, 513
anal fissure, 599
antacid, 137
Anthony, A. *see* Nygard, G.
Anthony, A., Dhillon, A.P., Thrasivoulou, C., Pounder, R.E. & Wakefield, A.J., Pre-ulcerative villous contraction and microvascular occlusion induced by indomethacin in the rat jejunum: a detailed morphological study, 605
anti-pyrine clearance, 263
antibiotic-associated colitis, 63
antibiotics, 63, 33
antidiarrhoeal agents, 87
antonomic nervous system, 599
antral ulceration, 167
apoptosis, 215
arachidonic acid, 403
Arany, Y. *see* Delfaux, M.
Arcari, M.L. *see* Morini, G.
Ardill, J.E.S. *see* Banerjee, S.
Armbrecht, J. *see* Kenyon, C.J.
Armstrong, G. *see* Lipscomb, G.R.
artificial nutritional support, 471
Ashraf, W., Park, F., Lof, J. & Quigley, E.M.M., Effects of psyllium therapy on stool characteristics, colon transit and anorectal function in chronic idiopathic constipation, 639
Ashworth, H.M. *see* Harris, A.W.
Atlan, P. *see* Delfaux, M.
Atoyebi, W. *see* Bell, G.D.
atrophic gastritis, 331
automicrobial therapy, 209
Avner, D. *see* Robinson, M.
Avner, D.L., Rorsch, E.R., Jennings, D.E., Greski-Rose, P.A. & The Lansoprazole Study Group, A comparison of three doses of lansoprazole (15, 30 and 60 mg) and placebo in the treatment of duodenal ulcer, 521
Axon, A.T.R. *see* Bell, G.D.
Axon, A.T.R., Review article: is *Helicobacter pylori* transmitted by the gastro-oral route?, 585
Ayres, R.C.S. *see* Reilly, T.G.

Bailey, R.J. *see* Thomson, A.B.R.
Banerjee, S., Ardill, J.E.S., Beattie, A.D. & McColl, K.E.L., Effect of omeprazole and feeding on plasma gastrin in patients with achlorhydria, 507
Bardhan, K.D. *see* Logan, R.P.H.
Bardhan, K.D., Dekkers, C.P.M., Lam, S.K., Nowak, A., Schaffalitzky de Muckadell, O.B., Schutze, K., Tildesley, G., Kler, L., Forster, J.K., Lacey, L.F., Roberts, P.M. & Isal, J.P., GR122311X (ranitidine bismuth citrate), a new drug for the treatment of duodenal ulcer, 497
Bardhan, K.D., Hawkey, C.J., Long, R.G., Morgan, A.G., Wormsley, K.G., Moules, I.K. & Brocklebank, D., Lansoprazole versus ranitidine for the treatment of reflux oesophagitis, 145
Baron, J.H. *see* Harris, A.W.
Baron, J.H. *see* Logan, R.P.H.
Barrett's oesophagus, 451
Bate, C.M. *see* Bell, G.D.
Bateman, D.N. *see* Roberts, S.J.
Beattie, A.D. *see* Banerjee, S.
Beattie, R.M., Goulding, N.J., Walker-Smith, J.A. & McDonald, T.T., Lipocortin-1 autoantibody concentration in children with inflammatory bowel disease, 541
Belaiche, J. *see* Corinaldesi, R.
Belaiche, J. *see* Lemann, M.
Bell, G.D., Bate, C.M., Axon, A.T.R., Tildesley, G., Kerr, G.D., Green, J.R.B., Emmas, C.E. & Taylor, M.D., Addition of metronidazole to omeprazole/amoxycillin dual therapy increases the rate of *Helicobacter pylori* eradication: a double-blind, randomized trial, 513
Bell, G.D., Powell, K.U., Burridge, S.M., Bowden, A.F., Atoyebi, W., Bolton, G.H., Jones, P.H. & Brown, C., Rapid eradication of *Helicobacter pylori* infection, 41
Bennett, M.K. *see* Brown, A.St.J.M.
Bentivoglio, A.R. *see* Albanese, A.
Berein, A. *see* Delmont, J.
Berein, A. *see* Jenkins, S.A.

© Blackwell Science Ltd

Berstad, A., Berstad, K., Wilhelmsen, I., Hatlebakk, J.G., Nesje, L.B. & Hausken, T., Spiramycin in triple therapy of *Helicobacter pylori*-associated peptic ulcer disease. An open pilot study with 12-month follow-up, 197
Berstad, K. *see* Berstad, A.
Bertaccini, G. *see* Morini, G.
Bhattacharya, K. *see* Goodman, M.J.
Bhupulan, A. *see* Heyman, T.D.
Bianchi Porro, G. *see* Lazzaroni, M.
bicarbonate, 251
bismuth, 447, 497
bleeding ulcer, 191
Blum, A.L. *see* Tytgat, G.N.J.
Bolton, G.H. *see* Bell, G.D.
Bomanji, J. *see* Heyman, T.D.
bone mineral density, 237
Bonnevie-Nielsen, V. *see* Davidsen, B.
botulinum toxin, 599
botulism, 599
Bounds, S.V.J. *see* Nygard, G.
Boureau, F. *see* Rampal, P.
Bowden, A.F. *see* Bell, G.D.
breath test, 11
Breese, E.J., Michie, C.A., Nicholls, S.W., Williams, C.B., Domizio, P., Walker-Smith, J.A. & MacDonald, T.T., The effect of treatment of lymphokine-secreting cells in the intestinal mucosa of children with Crohn's disease, 547
Brocklebank, D. *see* Bardhan, K.D.
bromodeoxyuridine, 571
Brown, A.St.J.M., Fiatarone, J.R., Wood, P., Bennett, M.K., Kelly, P.J., Rawlings, M.D., Day, C.P. & James, O.F.W., The effect of gastritis on human gastric alcohol dehydrogenase activity and ethanol metabolism, 57
Brown, C. *see* Bell, G.D.
Brown, C.M. & Rees, W.D.W., Review article: factors protecting the oesophagus against acid-mediated injury, 251
Brydon, W.G. *see* Hudson, N.
budesonide, 173, 557
Burridge, S.M. *see* Bell, G.D.

caecum, 403
caffeine clearance, 263
Cahill, R.J. *see* Sant, S.M.
Caldwell, J. *see* Nygard, G.
Canal, M. *see* Delfaux, M.
Canali, A. *see* Lazzaroni, M.
cancer, 215
Candida, 553
Caprilli, R. *see* Marcheggiano, A.
Capurso, L. *see* Papi, C.
carcinoid syndrome, 387
carcinoid tumours, 387
Casini-Raggi, V. *see* Laine, L.
Cassetta, E. *see* Albanese, A.
cathinone, 81
Celestin, L.R. *see* Logan, R.P.H.
Celik, A.F., Tomlin, J. & Read, N.W., The effect of oral vancomycin on chronic idiopathic constipation, 63
cell proliferation, 571
Celle, G. *see* Mansi, C.
Chauhan, S. *see* Kenyon, C.J.
Chiba, N. *see* Rademaker, J.W.
child, 541
childhood infection, 585
chronic hepatitis B, 535
Ciaco, A. *see* Papi, C.
cimetidine, 331
cisapride, 153, 271, 281, 661
clarithromycin, 201, 205, 209, 417
clinical success, 483
clinical trial, 209
clonidine, 179
Cole, R.A. *see* Yousfi, M.M.
Colin, R. *see* Corinaldesi, R.
colitis, 465
colon, 403
colonic motility, 63
colonic spreading, 161
Cominelli, F. *see* Laine, L.
comparative study, 411
Compston, J.E., Review article: osteoporosis, corticosteroids and inflammatory bowel disease, 237
constipation, 63
contraction, 605
Cook, G.A. *see* McAlindon, M.E.
Cook, M.K. *see* Roddie, P.
Cooper, B.T. *see* Neumann, C.S.
Corinaldesi, R., Valentini, M., Belaiche, J., Colin, R., Geldof, H., Maier, C. & The European Pantoprazole Study Group, Pantoprazole and omeprazole in the treatment of reflux oesophagitis: a European multicentre study, 667
Corrao, G. *see* Marcheggiano, A.
corticosteroids, 237
Cortot, A. *see* Lemann, M.
Cottrell, J. *see* Mann, S.G.
Cowan, H. *see* Kellow, J.E.
Crohn's colitis, 673
Crohn's disease, 75, 173, 315, 465, 547
cyclo-oxygenase, 227
CYP1A induction, 1
cytochrome P450, 363

Davidsen, B., Munkholm, P., Schlichting, P., Nielsen, O.H., Krarup, H. & Bonnevie-Nielsen, V., Tolerability of interferon alpha-2b, a possible new treatment of active Crohn's disease, 75
Day, C.P. *see* Brown, A.St.J.M.
De Boer, W.A. & Penston, J.G., Letters to the Editors, 85
De Boer, W.A., Driessen, W.M.M. & Tytgat, G.N.J., Only four days of quadruple therapy can effectively cure *Helicobacter pylori* infection, 633
De Bruin, H. *see* Smout, A.J.P.M.
Dekkers, C.P.M. *see* Bardhan, K.D.

© Blackwell Science Ltd

Delchier, J.-C., El Amine, I., Roudot-Thoraval, F., Elouacer-Blanc, L., Lamarque, D. & Stanescu, L., Maintenance of gastric pH above 6 with intravenous famotidine in patients with a bleeding duodenal ulcer, 191
Delfaux, M., Maisin, J.-M., Arany, Y., Atlan, P., Preito-Cabanis, M.-J., Canal, M. & Frexinos, J., The effects of lintopride, a 5HT-4 antagonist, on oesophageal motility, 563
Delmont, J., Hastier, P., Dumas, R., Jenkins, S.A. & Berein, A., Letters to the Editors, 581
Dhillon, A.P. *see* Anthony, A.
Dhillon, A.P. *see* Nygard, G.
Di Paolo, M. *see* Marcheggiano, A.
diabetes mellitus, 185, 529
diabetic gastroparesis, 179
diarrhoea, 87, 387, 441
dioxin-receptor, 1
disease, 349
diverticular disease, 33
Domizio, P. *see* Breese, E.J.
Domizio, P. *see* Katelaris, P.H.
dopamine receptor, 185
Dorrance, H. *see* Roddie, P.
double-blind, 411, 513, 521
Dreverman, J.W.M., Van Der Poel, A.J.M. & The Dutch Diarrhoea Trialists Group, Loperamide oxide in acute diarrhoea: a double-blind, placebo-controlled trial, 441
Driessen, W.M.M. *see* De Boer, W.A.
Drinkwater, C. *see* Heyman, T.D.
drug development, 457
drug safety, 441
drug-induced agramulocytosis, 711
Dumas, R. *see* Delmont, J.
duodenal ulcer, 287, 417, 425, 433, 497, 521
dyspepsia, 107

Eastwood, M.A. *see* Hudson, N.
Eckstein, R.P. *see* Kellow, J.E.
effervescent formulations, 51
efficacy, 411, 441
El Amine, I. *see* Delchier, J.-C.
El-Omar, E. *see* McColl, K.E.L.
El-Zimaity, H.M.T. *see* Yousfi, M.M.
Elewaut, A. *see* Lemann, M.
Elliott, S.L. *see* McAlindon, M.E.
Elouacer-Blanc, L. *see* Delchier, J.-C.
Emmas, C.E. *see* Bell, G.D.
enema, 293
enteral nutrition, 471, 547
eradication rates, 483
eradication, 41, 201, 417
erosive oesophagitis, 25, 145
erythromycin, 529
ethanol, 57
etodolac, 379
The European Pantoprazole Study Group *see* Corinaldesi, R.
Ewe, K., Ueberschaer, B., Press, A.G., Kurreck, C. & Klump, M., Effect of lactose, lactulose and bisacodyl on gastrointestinal transit studied by metal detector, 69
experimental colitis, 301

famotidine, 395
Farthing, M.J.G. *see* Katelaris, P.H.
Ferguson, A. *see* Hudson, N.
Fiatarone, J.R. *see* Brown, A.St.J.M.
fibre, 33
FK506, 301
fluconazole, 553
flushing, 387
Forbes, A. & Reading, N.G., Review article: the risks of malignancy from either immunosuppression or diagnostic radiation in inflammatory bowel disease, 465
Forster, J.K. *see* Bardhan, K.D.
Foss, M.C. *see* Rosa-E-Silva, L.
Fraser, A.G., Lewin, J.F. & Pounder, R.E., Gastric persorption of bismuth from ranitidine bismuth citrate, 447
free radicals, 301
Frexinos, J. *see* Delfaux, M.
Frieri, G. *see* Marcheggiano, A.
Froguel, E. *see* Lemann, M.
functional dyspepsia, 107, 117, 153

galactose elimination capacity, 263
Galian, A. *see* Lemann, M.
gall-bladder, 185
Gallo, Jr. L. *see* Rosa-E-Silva, L.
gamma scintigraphy, 161
Garner, A. *see* Parsons, M.E.
gastric acid inhibition, 649
gastric acid, 341, 521
gastric bleeding, 655
gastric emptying, 11, 81, 179
gastric histology, 57
gastric motility, 179
gastric mucosa, 655
gastric ulcer, 19
gastrin releasing peptides, 341
gastrin, 19, 341, 625
gastritis, 127
gastro-oesophageal reflux disease, 271
gastro-oral route, 585
gastrointestinal disease, 457
gastrointestinal motility, 529
gastroparesis, 107
gastroprotection, 685
Gaw, A.J., Williams, L.V., Spraggs, C.F. & Jordan, C.C., Role of pepsin in the development of indomethacin-induced antral ulceration in the rat, 167
Geldof, H. *see* Corinaldesi, R.
Genta, R.M. *see* Yousfi, M.M.
Geypens, B. *see* Perri, F.
Geypens, B.J. *see* Maes, B.D.
Ghoos, Y. *see* Perri, F.
Ghoos, Y.F. *see* Maes, B.D.
Giles, P. *see* Heyman, T.D.

© Blackwell Science Ltd

Gilvarry, J. *see* Sant, S.M.
glucocorticosteroids, 173
glucomannan, 33
GM-CSF, 711
Goodman, M.J. *see* Lipscomb, G.R.
Goodman, M.J., Bhattacharya, K. & Thompson, D.G., Letter to the Editors, 455
Goto, H. *see* Hoshino, H.
Goulding, N.J. *see* Beattie, R.M.
Graham, D.Y. *see* Yousfi, M.M.
Grandi, D. *see* Morini, G.
Green, J.R.B. *see* Bell, G.D.
Greski-Rose, P.A. *see* Avner, D.L.
Griffioen, G. *see* Van Ierssel, A.J.H.M.
Grossman, M.R. *see* Orr, W.C.
Guan, R., Ho, K.Y., Kang, J.Y., Yap, I., Gwee, K.A. & Tan, C.C., The effect of polyunsaturated phosphatitdyl chlorine in the treatment of acute viral hepatitis, 699
Guan, R., Ho, K.Y., Yap, I., Kang, J.Y., Tan, C.C., Ng, C., Smith, R. & Wee, A., Treatment of hepatitis B surface antigen carriers in the early stage of the infection using recominant alpha-interferon with steroid priming, 535
Gui, D. *see* Albanese, A.
Gummett, P.A. *see* Harris, A.W.
Gutz, H. *see* Witzel, L.
Gwee, K.A. *see* Guan, R.

24-h intragastric pH monitoring, 649
5HT-4 receptors, 563
H^+,K^+-ATPase, 363
H_2-blockers, 191, 331, 571
H_2-receptor antagonists, 51, 137
H_2-receptor blockers, 425
Hameeteman, W. *see* Houben, G.M.P.
Harris, A.G. & Redfern, J.S., Octreotide treatment of carcinoid syndrome: analysis of published dose-titration data, 387
Harris, A.W., Gummett, P.A., Logan, R.P.H., Ashworth, H.M., Baron, J.H. & Misiewicz, J.J., Eradication of *Helicobacter pylori* with lansoprazole and clarithromycin, 201
Hastier, P. *see* Delmont, J.
Hatlebakk, J.G. *see* Berstad, A.
Hausken, T. *see* Berstad, A.
Hawkey, C.J. *see* Bardhan, K.D.
Hawkey, C.J. *see* McAlindon, M.E.
Hayakawa, T. *see* Hoshino, H.
Hayes, P.C. *see* Jalan, R.
healing, 145, 497, 667
heartburn, 395
Helicobacter pylori, 41, 47, 107, 127, 197, 201, 205, 209, 327, 331, 417, 483, 497, 513, 585, 633
Hendel, J., Hendel, L. & Aggestrup, S., Morning or evening dosage of omeprazole for gastro-oesophageal reflux disease, 693
Hendel, L. *see* Hendel, J.
Herz, R. *see* Mossner, J.
Heyman, T.D., Bhupulan, A., Zureikat, N.E.K., Bomanji, J., Drinkwater, C., Giles, P. & Murray-Lyon, I.M., Khat chewing delays gastric emptying of a semi-solid meal, 81
Hiele, M. *see* Perri, F.
Hiele, M.I. *see* Maes, B.D.
Higson, D.L. *see* McDougle, A.M.A.
HIV, 553
Ho, K.Y. *see* Guan, R.
Holscher, A.H. *see* Mossner, J.
Hooi, J. *see* Houben, G.M.P.
Hooper, G. *see* Kenyon, C.J.
Hoschl, R. *see* Kellow, J.E.
Hoshino, H., Goto, H., Sugiyama, S., Hayakawa, T. & Ozawa, T., Effects of FK506 on an experimental model of colitis in rats, 301
Houben, G.M.P., Hooi, J., Hameeteman, W. & Stockbrugger, R.W., Twenty-four-hour intragastric acidity: rantitidine 300 mg b.d., 20 mg omeprazole o.m. vs. placebo, 649
Huber, R., Kohl, b., Sachs, G., Senn-Bilfinger, J., Simon, W.A. & Sturm, E., Review article: the continuing development of proton pump inhibitors with particular reference to pantoprazole, 363
Hudson, N., Brydon, W.G., Eastwood, M.A., Ferguson, A. & Palmer, K.R., Successful *Helicobacter pylori* eradication incorporating a one-week antibiotic regimen, 47
van der Hulst, R.W.M. *see* Keller, J.J.
humans, 655
Hunt, R.H. *see* Rademaker, J.W.
Hunter, J.O. *see* Reynolds, P.D.
Hutteman, W. *see* Witzel, L.
hypersensitive gut, 117

Iazigi, N. *see* Rosa-E-Silva, L.
Ileitis, 673
Ileocolitis, 673
immunosuppression, 465, 547
in vivo, 167
indocyanine green, 263
indomethacin, 167, 605, 615, 625
industrial research, 457
infantile hypertrophic sterosis, 599
inflammation, 215, 227
inflammatory bowel disease, 237, 315, 541
interferon alpha-2b, 75
interferon gamma, 547
interferon, 387
interleukin-2, 547
The International Mesasal Maintenance Study Group *see* Thomson, A.B.R.
intestinal absorption, 87
intestinal transit, 87
intracellular pH, 685
intragastric acidity, 625
intragastric monitoring, 51
intravenous, 191
Iqbal, T.H. *see* Neumann, C.S.
irritable bowel syndrome, 117
Irvine, E.J. *see* Marshall, J.K.
Isal, J.P. *see* Bardhan, K.D.
itraconazole, 327

© Blackwell Science Ltd

Jalan, R. & Hayes, P.C., Review article: quantitative tests of liver function, 263
James, O.F.W. *see* Brown, A.St.J.M.
Jenkins, S.A. & Berein, A., Review article: the relative effectiveness of somatostatin and octreotide therapy in pancreatic disease, 349
Jenkins, S.A. *see* Delmont, J.
Jennings, D.E. *see* Avner, D.L.
Jhala, N. *see* Robinson, M.
Johnson, D.M. *see* Rademaker, J.W.
Jones, P.H. *see* Bell, G.D.
Jonkman, J.H.G. *see* Smout, A.J.P.M.
Jordan, C.C. *see* Gaw, A.J.
Junien, J.L., Riviere, P., Review article: the hypersensitive gut—peripheral kappa agonists as a new pharmacological approach, 117

Kahrilas, P.J. *see* Pouderoux, P.
Kang, J.Y. *see* Guan, R.
kappa agonist, 117
Katelaris, P.H., Patchett, S.E., Zhang, Z.W., Domizio, P. & Farthing, M.J.G., A randomized prospective comparison of clarithomycin versus amoxycillin in combination with omeprazole for eradication of *Helicobacter pylori*, 205
Katragadda, R. *see* Minocha, A.
Keller, J.J., van der Hulst, R.W.M. & Tytgat, G.N.J., Treatment of *Helicobacter pylori* infection with a combination of itraconazole and omeprazole, 327
Kellow, J.E., Cowan, H., Shuter, B., Riley, J.W., Lunzer, M.R., Eckstein, R.P., Hoschl, R. & Lam, S.-K., Efficacy of cisapride therapy in functional dyspepsia, 153
Kelly, P.J. *see* Brown, A.St.J.M.
Kennedy, G. *see* Larouche, J.
Kenyon, C.J., Chauhan, S., Hooper, G., Marshall, S., McCracken, J.S., Staab, H.J. & Armbrecht, J., Colonic spreading of a non-chlorofluorocarbon mesalazine rectal foam enema in patients with quiescent ulcerative colitis, 161
Kerr, G.D. *see* Bell, G.D.
Khan, K. *see* Nygard, G.
Khat, 81
Kimmig, J.M., Treatment and prevention of relapse of mild oesophagitis with omeprazole and cisapride: comparison of two strategies, 281
Kiviluoto, T. *see* Kivinen, A.
Kivinen, A., Tarpila, S., Kiviluoto, T., Mustonen, H. & Kivlaakso, E., Milk and egg phospholipids act as protective surfactants against luminal acid in *Necturus* gastric mucosa, 685
Kivlaakso, E. *see* Kivinen, A.
Kler, L. *see* Bardhan, K.D.
Klinkenberg-Knol, E.C. *see* Kuipers, E.J.
Klump, M. *see* Ewe, K.
Koch, M. *see* Papi, C.
Kohl, B. *see* Huber, R.
Krarup, H. *see* Davidsen, B.
Kuipers, E.J., Lee, A., Klinkenberg-Knol, E.C. & Meuwissen, S.G.M., Review article: the development of atrophic gastritis—*Helicobacter pylori* and the effects of acid suppressive therapy, 331
Kurreck, C. *see* Ewe, K.

Lacey, L.F. *see* Bardhan, K.D.
lactose intolerance, 589
lactose malabsorption, 589
lactose nonpersistent, 589
lactose, 589
Laine, L. & Rabeneck, L., Prospective study of fluconazole-suspension for the treatment of oesophageal candidiasis in patients with AIDS, 553
Laine, L., Cominelli, F., Sloane, R., Casini-Raggi, V., Marin-Sorensen, M. & Weinstein, W.M., Interaction of NSAIDs and *Helicobacter pylori* on gastrointestinal injury and prostaglandin production: a controlled double-blind trial, 127
Lam, S.-K. *see* Kellow, J.E.
Lam, S.K. *see* Bardhan, K.D.
Lamarque, D. *see* Delchier, J.-C.
Lambert, C. *see* Larouche, J.
Lamers, C.B.H.W. *see* Van Ierssel, A.J.H.M.
Lancaster-Smith, M.J. *see* McDougle, A.M.A.
Landriault, H. *see* Larouche, J.
lansoprazole, 25, 145, 201, 521
The Lansoprazole Study Group *see* Avner, D.L.
large intestine, 215
Larouche, J., Morais, J., Picard, M., Lambert, C., Spenard, J., Landriault, H., Kennedy, G. & Poitras, P., Release of 5-ASA from Pentasa in patients with Crohn's disease of the small intestine, 315
Lazzaroni, M., Canali, A. & Bianchi Porro, G., Double- blind, randomized trial of roxatidine 150 mg in the early evening versus bedtime administration in the short-term treatment of duodenal ulcer, 425
Lee, A. *see* Kuipers, E.J.
Lemann, M., Galian, A., Rutgeerts, P., Van Heuverzwijn, R., Cortot, A., Viteau, J.M., Elewaut, A., Belaiche, J., Froguel, E. & Modigliani, R., Comparison of budesonide and 5-aminosalicylic acid enemas in active distal ulcerative colitis, 557
Levitt, M.D. *see* Suarez, F.L.
levosulpiride, 185
Lewin, J.F. *see* Fraser, A.G.
linotpride, 563
lipocortin, 541
Lipscomb, G.R., Wallis, N., Armstrong, G., Goodman, M.J. & Rees, W.D.W., Gastric mucosal adaptation to etodolac and naproxen, 379
Lof, J. *see* Ashraf, W.
Logan, R.P.H. *see* Harris, A.W.
Logan, R.P.H., Bardhan, K.D., Celestin, L.R., Theodossi, A., Palmer, K.R., Reed, P.I., Baron, J.H. & Misiewicz, J.J., Eradication of *Helicobacter pylori* and prevention of recurrence of duodenal ulcer: a randomized, double- blind, multi-centre trial of omeprazole with or without clarithromycin, 417
Long, R.G. *see* Bardhan, K.D.
loperamide oxide, 441
low dose, 395

© Blackwell Science Ltd

lower oesophageal sphincter, 251, 563
Lunzer, M.R. *see* Kellow, J.E.

MacDonald, T.T. *see* Breese, E.J.
Maes, B. *see* Perri, F.
Maes, B.D., Ghoos, Y.F., Geypens, B.J., Hiele, M.I. & Rutgeerts, P.J., Influence of octreotide on the gastric emptying of solids and liquids in normal healthy subjects, 11
Maier, C. *see* Corinaldesi, R.
maintenance treatment, 271, 281
maintenance, 287
Maisin, J.-M. *see* Delfaux, M.
malnutrition, 471
Mann, S.G., Murakami, A., McCarroll, K., Rao, A.N., Cottrell, J., Mehentee, J. & Morton, R., Low dose famotidine in the prevention of sleep distrubance caused by heartburn after an evening meal, 395
Mansi, C., Savarino, V., Vigneri, S., Sciaba, L., Perilli, D., Mele, M.R. & Celle, G., Effect of D_2-dopamine receptor antagonist levosulpiride on diabetic cholecystoparesis: a double-blind crossover study, 185
Marcheggiano, A., Caprilli, R., Frieri, G., Corrao, G., Valpiani, D., Di Paolo, M., Paoluzi, P. & Torsoli, A., Short-chain acid topical treatment in distal ulcerative colitis, 309
Maria, G. *see* Albanese, A.
Marin-Sorensen, M. *see* Laine, L.
Marshall, J.K. & Irvine, E.J., Rectal aminosalicylate therapy for distal ulcerative colitis: a meta-analysis, 293
Marshall, S. *see* Kenyon, C.J.
McAlindon, M.E., Cook, G.A., Elliott, S.L., Hawkey, C.J. & Yeomans, N.D., Gastric microbleeding following single and repeated dosing with naproxen, 655
McCarroll, K. *see* Mann, S.G.
McColl, K.E.L. & El-Omar, E., Review article: the relative effectiveness of somatostatin and octreotide therapy in pancreatic disease, 349
McColl, K.E.L. *see* Banerjee, S.
McCracken, J.S. *see* Kenyon, C.J.
McDonald, T.M. *see* Rademaker, J.W.
McDonald, T.T. *see* Beattie, R.M.
McDougle, A.M.A., Lancaster-Smith, M.J. & Higson, D.L., Ranitidine maintenance therapy in the prevention of duodenal ulceration; a comparison of 150 mg at night with 300 mg at night, 287
MEG-X, 263
Mehentee, J. *see* Mann, S.G.
Mele, M.R. *see* Mansi, C.
Mellow, M.H. *see* Orr, W.C.
mesalazine, 161, 315
metronidazole, 41, 209, 513
Meuwissen, S.G.M. *see* Kuipers, E.J.
Michie, C.A. *see* Breese, E.J.
microelectrode technique, 685
microvessels, 615
Middleton, S.J. *see* Reynolds, P.D.
milk and egg phospholipids, 685
milk, 589
Minocha, A., Katragadda, R., Rahal, P.S. & Ries, A., Erythromycin shortens orocaecal transit time in diabetic male subjects: a double-blind placebo-controlled study, 529
Misiewicz, J.J. *see* Harris, A.W.
Misiewicz, J.J. *see* Logan, R.P.H.
Modigliani, R. *see* Lemann, M.
Morais, J. *see* Larouche, J.
Morgan, A.G. *see* Bardhan, K.D.
Morini, G., Grandi, D., Arcari, M.L. & Bertaccini, G., Indomethacin-induced morphological changes in the rat gastric mucosa, with or without prior treatment with two proton pump inhibitors, 215
Morton, R. *see* Mann, S.G.
Mossner, J., Holscher, A.H., Herz, R. & Schneider, A., A double-blind study of pantoprazole and omeprazole in the treatment of reflux oesophagitis: a multicentre trial, 321
motility, 251
Moules, I.K. *see* Bardhan, K.D.
mucosal blood flow, 379
mucosal eicosanoids, 625
mucus, 251
Munkholm, P. *see* Davidsen, B.
Murakami, A. *see* Mann, S.G.
Murray-Lyon, I.M. *see* Heyman, T.D.
Mustonen, H. *see* Kivinen, A.
myeloperoxidase, 301

naproxen, 379, 655
natural killer cells, 173
necrosis, 215
neoplasm, 465
Nesje, L.B. *see* Berstad, A.
Neumann, C.S., Iqbal, T.H. & Cooper, B.T., Long term continous omeprazole treatment of patients with Barrett's oesophagus, 451
neutrophil, 301
Ng, C. *see* Guan, R.
Nicholls, S.W. *see* Breese, E.J.
Nielsen, O.H. *see* Davidsen, B.
night time, 395
nitric oxide, 227, 491
non-ulcer dyspepsia, 633
nonsteroidal anti-inflammatory drugs, 379, 571, 655
Nowak, A. *see* Bardhan, K.D.
NSAIDs, 127, 227, 403, 605
nutritional guidelines, 471
Nygard, G., Anthony, A., Khan, K., Bounds, S.V.J., Caldwell, J., Dhillon, A.P., Pounder, R.E. & Wakefield, A.J., Intestinal site-development susceptibility to chronic indomethacin in the rat: a morphological and biochemical study, 403

O'Morain, C.A. *see* Sant, S.M.
obesity, 599
octreotide, 11, 349, 387
oesophageal manometry, 563
oesophageal motility, 563
oesophageal reflux, 571

© Blackwell Science Ltd

oesophagitis, 661
oesophagus, 251, 553
Oliveria, R.B. *see* Rosa-E-Silva, L.
omeprazole metabolism, 1
omeprazole, 19, 41, 47, 137, 205, 209, 281, 321, 327, 331, 363, 411, 417, 451, 513, 649, 667
orocaecal transit, 529
Orr, W.C., Mellow, M.H. & Grossman, M.R., Patterns of 24-hour oesophageal acid exposure after acute withdrawal of acid suppression, 571
osteoporosis, 237
oxidants–toxicity, 215
Ozawa, T. *see* Hoshino, H.

pain measurement, 433
Palmer, K.R. *see* Hudson, N.; Logan, R.P.H.
pancreas, 349
pantoprazole, 19, 321, 363, 411, 667
Paoluzi, P. *see* Marcheggiano, A.
Papi, C., Ciaco, A., Koch, M. & Capurso, L., Efficacy of rifaximin in the treatmetn of symptomatic diverticular disease of the colon. A multicentre double-blind placebo-controlled trial, 33
parenteral nutrition, 471
Park, F. *see* Ashraf, W.
Parsons, M.E. & Garner, A., Review article: drug development in gastroenterology—the changing view of industry, 457
Patchett, S.E. *see* Katelaris, P.H.
pathogenesis, 107
pathophysiology, 179
Peeters, P.A.M. *see* Smout, A.J.P.M.
Pennington, C.R., Powell-Tuck, J. & Shaffer, J., Review article: artificial nutritional support for improved patient care, 471
Penston, J.G. *see* De Boer, W.A.
pepsin, 167
peptic ulcer disease, 197
peptic ulcer, 47, 209, 483, 633
Perilli, D. *see* Mansi, C.
peristalsis, 563
Perri, F., Maes, B., Geypens, B., Ghoos, Y., Hiele, M. & Rutgeerts, P., The influence of isolated doses of drugs, feeding and colonic bacterial ureolysis on urea breath test results, 705
persorption, 447
Petersen, K.-U., Review article: omeprazole and the cytochrome P450 system, 1
pH monitoring, 661
pharmaco-epidemiology, 137
pharmacokinetic, 363
Picard, M. *see* Larouche, J.
placebo, 521, 649
Poitras, P. *see* Larouche, J.
polyunsaturated phosphatidyl choline, 699
Pouderoux, P. & Kahrilas, P.J., A comparative study of cisapride and ranitidine at controlling oesophageal acid exposure in erosive oesophagitis, 661
Pounder, R.E. *see* Anthony, A.
Pounder, R.E. *see* Fraser, A.G.
Pounder, R.E. *see* Nygard, G.
Powell, K.U. *see* Bell, G.D.
Powell-Tuck, J. *see* Pennington, C.R.
Poxon, V. *see* Reilly, T.G.
prednisolone, 173
Preito-Cabanis, M.-J. *see* Delfaux, M.
Press, A.G. *see* Ewe, K.
prevention, 395
primary care, 137
prodrug, 441
prostaglandin E_2, 403
prostaglandins, 127, 227
prostanoids, 301
proton pump inhibition, 363
proton pump inhibitors, 19, 25, 331, 411, 521, 615

quadruple therapy, 633
quality of life, 433
Quigley, E.M.M. *see* Ashraf, W.

Rabeneck, L. *see* Laine, L.
Rachmilewitz, D. *see* Thomson, A.B.R.
Rademaker, J.W., Rainsford, K.D., Stetsko, P.I., Johnson, D.M., Chiba, N., McDonald, T.M. & Hunt, R.H., The effect of indomethacin-induced gastric mucosal injury on 24-h intragastric acidity and plasma gastrin concentration in healthy volunteers, 625
radiation, 465
Rahal, P.S. *see* Minocha, A.
Rainey, J.B. *see* Roddie, P.
Rainsford, K.D. *see* Rademaker, J.W.
Rampal, P., Ruszniewski, P., Boureau, F., Richards, A. & Slama, A., Pain and quality of life in patients with acute duodenal ulcer treated with ranitidine, 433
randomized trial, 557
ranitidine bismuth citrate, 447, 497
ranitidine, 25, 145, 287, 331, 433, 497, 649, 661
Rao, A.N. *see* Mann, S.G.
rat gastric mucosa, 615
Rawlings, M.D. *see* Brown, A.St.J.M.
Read, N.W. *see* Celik, A.F.
Reading, N.G. *see* orbes, A.
rectal foam, 161
recurrence, 417
Redfern, J.S. *see* Harris, A.G.
Reed, P.I. *see* Logan, R.P.H.
Rees, W.D.W. *see* Brown, C.M.
Rees, W.D.W. *see* Lipscomb, G.R.
reflux disease, 661
reflux oesophagitis, 271, 281, 321, 667
Rehner, M., Rohner, H.G. & Schepp, W., Comparison of pantoprazole versus omeprazole in the treatment of acute duodenal ulceration—a multicentre study, 411
Reilly, T.G., Ayres, R.C.S., Poxon, V. & Walt, R.P., *Helicobacter pylori* eradication in a clinical setting: success rates and the effect on the quality of life in peptic ulcer, 483
relapse, 271, 281, 497

© Blackwell Science Ltd

Reynolds, P.D., Middleton, S.J., Shorthouse, M. & Hunter, J.O., The effects of aminosalicylic acid derivatives on nitric oxide in a cell-free system, 491
Richards, A. *see* Rampal, P.
Ries, A. *see* Minocha, A.
rifaximin, 33
Riley, J.W. *see* Kellow, J.E.
Riviere, P. *see* Junien, J.L.
Roberts, P.M. *see* Bardhan, K.D.
Roberts, S.J. & Bateman, D.N., Prescribing of antacids and ulcer-healing drugs in primary care in the north of England, 137
Robinson, M., Sahba, B., Avner, D., Jhala, N., Greski-Rose, P.A. & Jennings, D.E., A comparison of lansoprazole and ranitidine in the treatment of erosive oesophagitis, 25
Roddie, P., Dorrance, H., Cook, M.K. & Rainey, J.B., Treatment of sulphasalazine-induced agranulocytosis with granulocyte macrophage-colony stimulating factor, 711
Rohner, H.G. *see* Rehner, M.
Rorsch, E.R. *see* Avner, D.L.
Rosa-E-Silva, L., Troncon, L.E.A., Oliveria, R.B., Iazigi, N., Gallo, Jr. L. & Foss, M.C., Treatment of diabetic gastroparesis with oral clonidine, 179
Roudot-Thoraval, F. *see* Delchier, J.-C.
roxatidine, 425
Ruszniewski, P. *see* Rampal, P.
Rutgeerts, P. *see* Lemann, M.
Rutgeerts, P. *see* Perri, F.
Rutgeerts, P.J. *see* Maes, B.D.

Sachs, G. *see* Huber, R.
Sahba, B. *see* Robinson, M.
saliva, 251
Sant, S.M., Cahill, R.J., Gilvarry, J. & O'Morain, C.A., Do non-steroidal anti-inflammatory drugs have an effect on gastric cell turnover?, 575
Savaiano, D.A. *see* Suarez, F.L.
Savarino, V. *see* Mansi, C.
Schaffalitzky de Muckadell, O.B. *see* Bardhan, K.D.
Schepp, W. *see* Rehner, M.
Schepp, W. *see* Witzel, L.
Schiller, L.R., Review article: anti-diarrhoeal pharmacology and therapeutics, 87
Schlichting, P. *see* Davidsen, B.
Schneider, A. *see* Mossner, J.
Schutze, K. *see* Bardhan, K.D.
Sciaba, L. *see* Mansi, C.
secretion, 251
Senn-Bilfinger, J. *see* Huber, R.
sensation, 107
Shaffer, J. *see* Pennington, C.R.
short-chain fatty acids, 309
Shorthouse, M. *see* Reynolds, P.D.
Shuter, B. *see* Kellow, J.E.
Simon, W.A. *see* Huber, R.
Slama, A. *see* Rampal, P.
sleep disturbance, 395
Sloane, R. *see* Laine, L.
small intestine, 215, 315, 403
Smith, R. *see* Guan, R.
Smout, A.J.P.M., Jonkman, J.H.G., Peeters, P.A.M. & De Bruin, H., Effect of an evening dose of regular and effervescent formulations of ranitidine or cimetidine on intragastric pH in healthy volunteers, 51
somatostatin, 349
Spenard, J. *see* Larouche, J.
spiramycin, 197
Spraggs, C.F. *see* Gaw, A.J.
Staab, H.J. *see* Kenyon, C.J.
Stanescu, L. *see* Delchier, J.-C.
steroid priming, 535
steroid resistance, 541
Stetsko, P.I. *see* Rademaker, J.W.
Stockbrugger, R.W. *see* Houben, G.M.P.
Sturm, E. *see* Huber, R.
Suarez, F.L., Savaiano, D.A. & Levitt, M.D., Review article: the treatment of lactose intolerance, 589
substituted benzimidazoles, 667
Sugiyama, S. *see* Hoshino, H.
sulphasalazine, 711
suppository, 293
symptom relief, 145

Talley, N.J., Review article: functional dyspepsia—should treatment be targeted on disturbed physiology?, 107
Tan, C.C. *see* Guan, R.
Tarpila, S. *see* Kivinen, A.
Taylor, M.D. *see* Bell, G.D.
Theodossi, A. *see* Logan, R.P.H.
Thompson, D.G. *see* Goodman, M.J.
Thomson, A.B.R., Wright, J.P., Vatn, M., Bailey, R.J., Rachmilewitz, D., Adler, M. & Wilson-Lynch, K.A., on behalf of The International Mesasal Maintenance Study Group, Mesalazine (Mesasal/Claversal) 1.5 g b.d. vs. placebo in the maintenance of remission of patients with Crohn's disease, 673
Thrasivoulou, C. *see* Anthony, A.
Tigley, A.W. *see* Wallace, J.L.
Tildesley, G. *see* Bardhan, K.D.
Tildesley, G. *see* Bell, G.D.
Tomlin, J. *see* Celik, A.F.
topical therapy, 293
Torsoli, A. *see* Marcheggiano, A.
transmission, 585
treatment, 107, 179, 205
triple therapy, 197, 633
Troncon, L.E.A. *see* Rosa-E-Silva, L.
Tytgat, G.N.J. *see* De Boer, W.A.
Tytgat, G.N.J. *see* Keller, J.J.
Tytgat, G.N.J., Blum, A.L. & Verlinden, M., Prognostic factors for relapse and maintenance treatment with cisapride in gastro-oesophageal reflux disease, 271

Ueberschaer, B. *see* Ewe, K.
ulcer, 605
ulcerative colitis, 161, 293, 309, 491, 557
ultrasound, 185

© Blackwell Science Ltd

vagotomy, 331
Valentini, M. *see* Corinaldesi, R.
Valpiani, D. *see* Marcheggiano, A.
Van Der Sluys Veer, A. *see* Van Ierssel, A.J.H.M.
Van Heuverzwijn, R. *see* Lemann, M.
Van Hogezand, R.A. *see* Van Ierssel, A.J.H.M.
Van Ierssel, A.J.H.M., Van Der Sluys Veer, A., Verspaget, H.W., Griffioen, G., Van Hogezand, R.A. & Lamers, C.B.H.W., Budesonide and prednisolone suppress peripheral bolld natural killer cells in Crohn's disease, 173
Vatn, M. *see* Thomson, A.B.R.
Verlinden, M. *see* Tytgat, G.N.J.
Verspaget, H.W. *see* Van Ierssel, A.J.H.M.
Viggiano, A. *see* Albanese, A.
Vigneri, S. *see* Mansi, C.
villi, 605
Viteau, J.M. *see* Lemann, M.
vomiting, 585

Wakefield, A.J. *see* Anthony, A.
Wakefield, A.J. *see* Nygard, G.
Walker-Smith, J.A. *see* Beattie, R.M.
Walker-Smith, J.A. *see* Breese, E.J.
Wallace, J.L. & Tigley, A.W., Review article: new insights into prostaglandins and mucosal defence, 227
Wallis, N. *see* Lipscomb, G.R.
Walt, R.P. *see* Reilly, T.G.
Watson, A.J.M., Review article: manipulation of cell death—the development of novel strategies for the treatment of gastrointestinal disease, 215
Wee, A. *see* Guan, R.
Weinstein, W.M. *see* Laine, L.
Wilhelmsen, I. *see* Berstad, A.
Williams, C.B. *see* Breese, E.J.
Williams, L.V. *see* Gaw, A.J.
Wilson-Lynch, K.A. *see* Thomson, A.B.R.
Witzel, L., Gutz, H., Hutteman, W. & Schepp, W., Pantoprazole versus omeprazole in the treatment of acute gastric ulcers, 19
Wood, P. *see* Brown, A.St.J.M.
Wormsley, K.G. *see* Bardhan, K.D.
Wright, J.P. *see* Thomson, A.B.R.

Yap, I. *see* Guan, R.
Yeomans, N.D. *see* McAlindon, M.E.
Yousfi, M.M., El-Zimaity, H.M.T., Al-Assi, M.T., Cole, R.A., Genta, R.M. & Graham, D.Y., Metronidazole, omeprazole and clarithromycin: an effective combination therapy for *Helicobacter pylori* infection, 209

Zhang, Z.W. *see* Katelaris, P.H.
Zureikat, N.E.K. *see* Heyman, T.D.

© Blackwell Science Ltd